ASPN vs IOVA
ASPN: Aspen Aerogels provides high-performance aerogel insulation solutions engineered for energy efficiency and thermal management in electric vehicle batteries and industrial energy applications. IOVA: Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma through centralized manufacturing and clinical innovation.
Side-by-side fundamentals
| Metric | ASPN | IOVA | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $6.89 | $6.21 | |
| Market cap as of 2026-08-08 | $571M | $2.8B | |
| Net margin as of 2026-08-08 | -48.6% | -123.9% | ASPN higher |
| Gross margin as of 2026-08-08 | +11.9% | +36.7% | IOVA higher |
| Operating margin as of 2026-08-08 | -43.3% | -127.2% | ASPN higher |
| ROE as of 2026-08-08 | -42.1% | -50.2% | ASPN higher |
| ROA as of 2026-08-08 | -24.4% | -38.8% | ASPN higher |
| Debt / equity as of 2026-08-08 | 0.49 | 0.00 | IOVA lower |
| Revenue growth (YoY) as of 2026-08-08 | -47.3% | +34.3% | IOVA higher |
| Revenue CAGR (3y) SEC XBRL | +14.5% | +1388.7% | IOVA higher |
| Beta as of 2026-08-08 | 3.16 | 0.84 | |
| 1-year return as of 2026-08-06 close | -16.4% | +140.7% | IOVA higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.